05:30 PM EDT, 10/08/2024 (MT Newswires) -- Insmed ( INSM ) said late Tuesday that new subgroup findings in the phase 3 ASPEN trial of its brensocatib for the treatment of noncystic fibrosis bronchiectasis are consistent with the "positive" overall trial results.

The data showed "the annualized rate of pulmonary exacerbations favored brensocatib at both the 10 mg and 25 mg doses over placebo for almost all subgroups," the company said. It added that the drug was well-tolerated in the study.

The company plans to file a new drug application with the US Food and Drug Administration for brensocatib in patients with bronchiectasis in Q4. It is looking at a US launch by mid-2025 and launches in Europe and Japan in 2026.

Shares of the company rose 2% in after-hours activity.

Price: 72.80, Change: +1.43, Percent Change: +2.00